Detalhe da pesquisa
1.
Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission - results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial.
BMC Cancer
; 22(1): 147, 2022 Feb 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35123422
2.
Stability and uniqueness of clonal immunoglobulin CDR3 sequences for MRD tracking in multiple myeloma.
Am J Hematol
; 94(12): 1364-1373, 2019 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31571261